-
Je něco špatně v tomto záznamu ?
Clinical Efficacy of Blood Ultrafiltration Therapy in Patients with Acute Decompensated Chronic Heart Failure Running Title: Blood Ultrafiltration Therapy for Heart Failure
YW. He, FQ. Wang, FF. Zhang, HZ. Chen
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 1991
Free Medical Journals
od 1998
PubMed Central
od 2020
ProQuest Central
od 2005-01-01
Medline Complete (EBSCOhost)
od 2006-01-01
Nursing & Allied Health Database (ProQuest)
od 2005-01-01
Health & Medicine (ProQuest)
od 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1998
- MeSH
- biologické markery MeSH
- diuretika terapeutické užití MeSH
- funkce levé komory srdeční fyziologie MeSH
- kreatinin MeSH
- lidé MeSH
- natriuretický peptid typu B * MeSH
- peptidové fragmenty MeSH
- renin MeSH
- srdeční selhání * MeSH
- tepový objem fyziologie MeSH
- ultrafiltrace MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
In this study, we investigated the clinical effects of blood ultrafiltration therapy in patients with acute decompensated chronic heart failure. We enrolled 78 patients with acute decompensated chronic heart failure who were admitted to a hospital from September 2017 to December 2021, and divided them into two groups based on the digital randomization method. The FQ-16 heart failure ultrafiltration dehydrating device blood ultrafiltration therapy was administered to the observation group (39 patients) for 8-16 hours, while the control group (39 patients) received the stepped drug therapy. Echocardiography was used to assess the changes in cardiac function of the patients in both groups before and after treatment. The changes in urine volume, N-terminal pro-B-type natriuretic peptide (NT-proBNP), plasma renin, and serum creatinine levels were measured before and after the treatment to compare the overall response rate of the patients in both groups. The differences in left ventricular end-systolic dimension and left ventricular end-diastolic dimension and the ejection fraction between the groups before treatment were not statistically significant (P > 0.05), however, the left ventricular end-diastolic dimension in the observation group was significantly lower and the ejection fraction was significantly higher (P < 0.05) compared with that before treatment; the urine volume, N-terminal pro-B-type natriuretic peptide (NT-proBNP), plasma renin, and serum creatinine were significantly improved in both groups after treatment compared with that before treatment. All indexes in the observation group were better than those in the control group (P < 0.05), 74.36%. The overall response rate of the observation group was 94.87%, x2 = 4.843 and the difference between groups was statistically significant (P < 0.05). Blood ultrafiltration therapy for patients with acute decompensated chronic heart failure can improve their cardiac and renal functions, reduce NT-proBNP, reduce volume load, and enhance efficacy while ensuring high safety.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24003174
- 003
- CZ-PrNML
- 005
- 20250416104649.0
- 007
- ta
- 008
- 240220s2023 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.935073 $2 doi
- 035 __
- $a (PubMed)38215058
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a He, Yan-Wei $u Department of Cardiology, The First People's Hospital of Yangquan, Yangquan, China
- 245 10
- $a Clinical Efficacy of Blood Ultrafiltration Therapy in Patients with Acute Decompensated Chronic Heart Failure Running Title: Blood Ultrafiltration Therapy for Heart Failure / $c YW. He, FQ. Wang, FF. Zhang, HZ. Chen
- 520 9_
- $a In this study, we investigated the clinical effects of blood ultrafiltration therapy in patients with acute decompensated chronic heart failure. We enrolled 78 patients with acute decompensated chronic heart failure who were admitted to a hospital from September 2017 to December 2021, and divided them into two groups based on the digital randomization method. The FQ-16 heart failure ultrafiltration dehydrating device blood ultrafiltration therapy was administered to the observation group (39 patients) for 8-16 hours, while the control group (39 patients) received the stepped drug therapy. Echocardiography was used to assess the changes in cardiac function of the patients in both groups before and after treatment. The changes in urine volume, N-terminal pro-B-type natriuretic peptide (NT-proBNP), plasma renin, and serum creatinine levels were measured before and after the treatment to compare the overall response rate of the patients in both groups. The differences in left ventricular end-systolic dimension and left ventricular end-diastolic dimension and the ejection fraction between the groups before treatment were not statistically significant (P > 0.05), however, the left ventricular end-diastolic dimension in the observation group was significantly lower and the ejection fraction was significantly higher (P < 0.05) compared with that before treatment; the urine volume, N-terminal pro-B-type natriuretic peptide (NT-proBNP), plasma renin, and serum creatinine were significantly improved in both groups after treatment compared with that before treatment. All indexes in the observation group were better than those in the control group (P < 0.05), 74.36%. The overall response rate of the observation group was 94.87%, x2 = 4.843 and the difference between groups was statistically significant (P < 0.05). Blood ultrafiltration therapy for patients with acute decompensated chronic heart failure can improve their cardiac and renal functions, reduce NT-proBNP, reduce volume load, and enhance efficacy while ensuring high safety.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a natriuretický peptid typu B $7 D020097
- 650 _2
- $a ultrafiltrace $7 D014462
- 650 _2
- $a renin $7 D012083
- 650 _2
- $a kreatinin $7 D003404
- 650 12
- $a srdeční selhání $7 D006333
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a diuretika $x terapeutické užití $7 D004232
- 650 _2
- $a peptidové fragmenty $7 D010446
- 650 _2
- $a tepový objem $x fyziologie $7 D013318
- 650 _2
- $a funkce levé komory srdeční $x fyziologie $7 D016277
- 650 _2
- $a biologické markery $7 D015415
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Wang, Feng-Qin $u Department of Cardiology, The First People's Hospital of Yangquan, Yangquan, China
- 700 1_
- $a Zhang, Fen-Fang $u Department of Cardiology, The First People's Hospital of Yangquan, Yangquan, China
- 700 1_
- $a Chen, Huan-Zhen $u Department of Cardiology, The First People's Hospital of Yangquan, Yangquan, China
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 72, č. 6 (2023), s. 701-706
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38215058 $y Pubmed
- 910 __
- $a ABA008 $b A 4120 $c 266 $y p $z 0
- 990 __
- $a 20240220 $b ABA008
- 991 __
- $a 20250416104654 $b ABA008
- 999 __
- $a ok $b bmc $g 2302953 $s 1212914
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 72 $c 6 $d 701-706 $e 20231231 $i 1802-9973 $m Physiological research $n Physiol Res $x MED00003824
- LZP __
- $b NLK116 $a Pubmed-20240220